CagriSema Cuts Weight 23–27% Across Menopause Stages, Trial Analysis Shows
A REDEFINE 1 post-hoc analysis reports CagriSema produced 23.1%–26.7% mean weight loss in women across menopause stages, with an FDA decision anticipated in late 2026.
A REDEFINE 1 post-hoc analysis reports CagriSema produced 23.1%–26.7% mean weight loss in women across menopause stages, with an FDA decision anticipated in late 2026.